Procuritas Creates New IT Services Platform in Finland
16.6.2021 11:00:00 EEST | Business Wire | Press release
Procuritas Capital Investors VI (“Procuritas”) today announces the launch of Frendy, a new IT services platform based in Finland. The new company has been created through the acquisition of twelve IT services businesses across the country. After the transaction, Procuritas will become the majority shareholder, with the current entrepreneurial teams continuing in the day-to-day management of their local businesses with significant minority ownership of the wider company.
Frendy will deliver IT services for SME companies in Finland, a target market of more than €1 billion per annum. At inception, the company will have 160 employees in 16 locations across Finland and will be headquartered in Helsinki, with revenues in excess of €33 million.
Jussi Holopainen, Investment Manager at Procuritas, commented, “We are delighted to have completed the formation of Frendy. It is a really exciting opportunity for Procuritas to create a new company in this sizeable fragmented market currently serving SME customers in Finland.”
“With an experienced management team and board in place and potential for further acquisitions, Procuritas is looking forward to repeating another transformative growth journey through a service industry consolidation which has proven successful many times throughout its 35-year history”, says Johan Conradsson, co-Managing Partner at Procuritas.
Incoming Frendy CEO, Mikko Peltonen, added, “Frendy operates in a large market where there are a limited number of nationwide players. Bringing together these twelve businesses creates fantastic opportunities for improved customer service through consolidation and even closer local support while increasing profitability through centralised purchasing and shared systems.”
The central Frendy management team will be led by CEO Mikko Peltonen who has a background in corporate finance, including M&A advisory in the IT services space, as well as industry, and was most recently CEO of Rostek, the facade access equipment company. With a long history in the IT industry as CEO of Vincit and Jolla, and currently Chief Digital Officer at Finnair, Tomi Pienimäki becomes Chairman of the Board. Another technology industry veteran, Jyrki Rosenberg, who has led multiple global technology businesses in companies such as F-Secure, joins the Board.
About Procuritas
Procuritas is a mid-market Nordic private equity investor, building up niche market-leading companies through transformative growth in service industry consolidations, digital consumer businesses, software and select industrial sectors. As the longest-established private equity firm in the Nordics with a 35-year track record, Procuritas has carefully invested in more than 45 companies, accelerating their growth and helping them to realize their true business potential. The long-serving team is characterised by its passion for business, hands-on experience, enthusiasm, commitment to ESG-linked value creation initiatives and strong belief that they are allies in the quest to build strong and sustainable businesses. Read more at www.procuritas.com.
About Frendy
Frendy is an IT service provider for SMEs in Finland. Headquartered in Helsinki, it delivers IT support, IT security, equipment, networks, data centre and cloud services as well as document handling solutions via its local offices across the country. Frendy has been created through the acquisition of 12 companies which include Indatahouse Oy, Indata Oy, ItsPro Oy, Isoweli Oy, Tietokonemaailma Oy, Datanix Oy, Wintunix Oy, R-Office Oy, R-Office Uusimaa Oy, R-Office Itä-Suomi Oy, Soluto and Mikrovirta. Read more at www.frendy.fi.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005044/en/
Contact information
Mikko Peltonen
CEO, Frendy Oy
+358 40 520 1458 / mikko.peltonen@frendy.fi
Jussi Holopainen
Investment Manager, Procuritas
+46 70 333 55 67 / jussi.holopainen@procuritas.com
Johan Conradsson
Partner, Procuritas
+46 76 109 99 44 / johan.conradsson@procuritas.com
Media – Kepler Communications
Charlotte Balbirnie
+44 7989 528421 / CBalbirnie@keplercomms.com
Caroline Villiers
+44 7808 585184 / CVilliers@keplercomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom